MaxCyte, Inc. (MXCT)
After hours:
| Previous close | 4.8000 |
| Open | 4.8500 |
| Bid | 4.6300 x 100 |
| Ask | 4.6900 x 200 |
| Day's range | 4.6600 - 4.8850 |
| 52-week range | 2.4500 - 5.5450 |
| Volume | |
| Avg. volume | 560,692 |
| Market cap | 497.439M |
| Beta (5Y monthly) | 1.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
ROCKVILLE, Md., May 07, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced its first quarter ended March 31, 2024 financial results and updated its 2024 guidance. First Quarter Highlights Total revenue of $11.3 million in the first quarter of
- GlobeNewswire
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
ROCKVILLE, Md., April 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the first quarter 2024 after the U.S. market close on Tuesday, May 7th, 2024. Company management will host a conference cal
- GlobeNewswire
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programsROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications and Be Biopharma (“Be Bio”), a company pioneer
